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of therapy. A review of clinical literature was conducted. Utility
was estimated from a survey of the general public using a time-
trade-offmethodology. Costswere calculated from the perspective
of the UK National Health Service. Future costs and beneﬁts were
discounted at 3.5%. RESULTS: When overall survival (OS) was
assumed to be equal, treatment with alemtuzumab instead of
chlorambucil increased lifetime cost per patient from £10,957 to
£17,938 and increased QALYs per patient from 1.59 to 1.96 at a
cost of £18,788 per QALY gained. When OS was allowed to vary
to reﬂect differences in progression free survival the cost perQALY
fell to £14,604. Findings were most sensitive to the cost of the
interventions, response rate and duration at ﬁrst line. CONCLU-
SIONS:This study found that in theUK, the cost perQALYgained
with ﬁrst-line alemtuzumab therapy over chlorambucil is £18,788
in high-risk (17p-) CLL patients.
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OBJECTIVES: To conduct a cost utility analysis of docetaxel-
doxorubicin (AT) vs standard doxorubicin-cyclophosphamide
(AC) chemotherapy as neoadjuvant therapy for patients with
locally advanced breast cancer in Poland. METHODS: We devel-
oped a cost-utility Markov model from a public payers’ perspec-
tive (National Health Fund), using clinical data from published
sources, Polish cost data, and a lifetime horizon.RESULTS: Based
on a systematic review, only one randomized clinical trial
was included in the comparison: AT (docetaxel 75 mg/m2 +
doxorubicin 50 mg/m2, every 3weeks,mean number of cycles 5.5)
vs AC (doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2,
every 3 weeks, mean number of cycles 5.5). Average costs of the
treatment for locally advanced breast cancer (including neoadju-
vant chemotherapy, treatment of serious adverse events, surgery,
additional post-operative therapy, health state monitoring, local
and distant relapse treatment and palliative care) were 53,677
PLN for AT and 33,716 PLN for AC. Treatment effects (per
patient) were 8,258 QALY and 9,081 LYG for AT and 7,191
QALYand 8, 075LYG forAC. ICER for theAT vsAC comparison
were 18,729 PLN/QALY and 19,842 PLN/LYG. The ICER values
were below the acceptable threshold for very cost-effective treat-
ment in Poland (27 000 PLN). CONCLUSIONS: The docetaxel
regimen is more effective and more expensive in the neoadjuvant
treatment of patients with locally advanced breast cancer com-
pared with AC chemotherapy. ICERs are below the acceptable
threshold, therefore the docetaxel therapy can be considered a
cost-effective treatment for locally advanced BC in Poland.
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OBJECTIVES: Rituximab has recently received European
approval for its use in combination with any chemotherapy. The
aim of this study is to evaluate the cost-effectiveness of rituximab
added to the most commonly used chemotherapy regimens, per-
formed from the Spanish National Health System perspective.
METHODS: We developed a Markov model based on 3 random-
ized controlled clinical trials comparing the addition of ritux-
imab to chemotherapy regimens of CVP; MCP or CHOP vs
chemotherapy alone, in patients with advanced follicular lym-
phoma. Progression-free survival (PFS) and overall survival were
the endpoints evaluated in these trials. Rates of disease progres-
sion were derived from the PFS Kaplan-Meier curves, mortality
rates were obtained from the Scotland-Newcastle Lymphoma
Group database and Spanish age-speciﬁc mortality tables;
resource consumption data was based on a local expert panel
questionnaire and patient utilities to account for quality of life
were applied to the PFS and progressed health states. Medication
and supportive care costs, and quality-adjusted life years
(QALYs) were estimated over 10 years and discounted at 3.5%.
Univariate and probabilistic sensitivity analysis were performed.
RESULTS: The addition of rituximab to chemotherapy increased
QALYs by 0.795, 1.129 and 0.971 years for CVP, MCP and
CHOP, respectively, compared to chemotherapy alone. The
incremental cost per QALY gained was €10,190, €6,092 and
€7,855, for CVP, MCP and CHOP, respectively. The incremental
cost per life year gained was €10,168, €6,348 and €8,190, for
CVP, MCP and CHOP, respectively. Sensitivity analyses indicated
the results were robust, and most sensitive to the duration of
treatment effect and time horizon. CONCLUSIONS: The addi-
tion of rituximab to any of the chemotherapy regimens evalu-
ated, was estimated to increase quality-adjusted life expectancy,
and be a highly cost-effective treatment option for patients with
advanced follicular lymphoma.
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OBJECTIVES: To assess the cost-effectiveness of treating, in an
observational setting, ﬁrst-line Chronic Lymphocytic Leukaemia
(CLL) patients in the USA with Rituximab, Fludarabine and
Cyclophosphamide (R-FC) versus FC alone (Tam et al., 2008).
METHODS: A 3-state semi-Markov model was developed with
rates of disease progression obtained from the Progression Free
Survival curves (R-FC n = 300; FC n = 108, 6 year median
follow-up) using the best ﬁt (Weibull) function, and rates of
death in the PFS and progressed states based on background
mortality and observed CLL mortalities respectively. Published
utility values of 0.8 and 0.6 were applied to PFS and progressed
health states and no treatment beneﬁt was assumed beyond the
observational period. Costs were estimated using Medicare reim-
bursed rates, MS-DRGs for CLL and published drug prices, and
include the cost of administration and adverse events. Costs (in
USD) and quality-adjusted life-years (QALYs) were estimated
over a lifetime horizon (30 years) and discounted at 3% per
annum. RESULTS: Average lifetime health service costs per
patient were $51,694, and $29,192 for R-FC and FC respec-
tively. Life expectancy was estimated as 9.9 years for R-FC and
7.7 years for FC. Average QALYs for R-FC and FC were 7.3 and
5.5 years respectively. The incremental cost-effectiveness ratio for
R-FC compared to FC was $10,291 per life year gained and
$12,382 per QALY gained. The modeled results were robust to
sensitivity analyses assessing the uncertainty about costs and
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efﬁcacy. CONCLUSIONS: In CLL patients, ﬁrst-line treatment
with R-FC in the observational setting signiﬁcantly extends life
expectancy and is a cost-effective alternative to FC.
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OBJECTIVES: To assess the lifetime cost-effectiveness (CE) of
oral topotecan (Hycamtin(r) Hard Capsules) plus best supportive
care (BSC) versus BSC alone in patients with relapsed SCLC in
the UK. METHODS: In an international randomised phase III
trial, patients with relapsed SCLC not considered as candidates
for standard intravenous therapy were randomly assigned to oral
topotecan (OT) plus BSC (n = 71) or to BSC alone (n = 70) and
followed until death. Median survival with BSC was 13.9 weeks
(95% CI, 11.1 to 18.6) and with OT, 25.9 weeks (95% CI, 18.3
to 31.6). Patients on OT had slower deterioration in health
related quality of life and greater symptom control. A CE model
using patient level data was developed to estimate the lifetime
incremental cost per quality adjusted life year (QALY) gained of
OT + BSC versus BSC alone. UK unit costs and an assumed drug
acquisition cost were included to estimate lifetime CE from the
perspective of the UK National Health Service (NHS). Outcomes
were measured in QALYs based on individual residual life
expectancy data and health related quality of life (EQ5D) col-
lected during the trial. The cost components were drug acquisi-
tion costs, drug administration costs, monitoring costs, costs of
treating haematological and non-haematological adverse events,
and costs of providing care in the additional months of life
attributable to OT + BSC. RESULTS: The base case estimate of
the incremental cost per QALY gained was £25,709. The results
were sensitive to the drug acquisition cost for OT. Subgroup
analysis showed that OT + BSC was more CE among patients
with rapid disease progression (i.e. treatment free interval <=60
days) (cost/QALY = £16,957), with worse performance status
(i.e. PS 2) (£24,783), and with no liver metastasis (£20,345).
CONCLUSIONS: In patients with relapsed SCLC OT + BSC
represents a cost-effective treatment option versus BSC alone
from the perspective of the UK NHS.
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OBJECTIVES: Despite the high incidence of NSCLC, little is
known about associated economic burdens experienced by
patients and caregivers. In a longitudinal study of newly diag-
nosed stage IV NSCLC patients we calculated estimates of out-
of-pocket costs (OPC) and time costs (TC) for patients and
caregivers. We also explored the relationship between OPC and
sociodemographic and clinical factors. METHODS: Patients
and their surrogates were asked to report OPC and TC in
monthly diaries and surveys. Monthly costs were compared in 2
disease phases: terminal phase (TP) within 2 months of death,
and initial phase (IP) from diagnosis until 2 months before death
(2007 US $). RESULTS: Among 196 patients, 129 received initial
chemotherapy and 67 received best supportive care. Mean age
was 59 years and median income was $60,000; 40% were
employed. Initial treatment choice was not associated with OPC,
but phase of illness was. Monthly mean OPCs were $372 and
$582 (p-value = 0.02) during IP and TP. Prescription medications
and transportation accounted for 22% v. 27%, and 15% v. 37%,
of total OPC in IP and TP, respectively. In TP, mean monthly
wage losses of $1835 for patients and $419 for caregivers were
reported. 87 respondents (48%) reported usage of complemen-
tary and alternative therapy, at a mean monthly cost of $107
among users. 86% of surrogates reported some effect of caregiv-
ing on work, including job loss in 6%. Costs of lost leisure time
for caregivers were signiﬁcantly higher in TP compared to IP, at
$3682 vs. $1579 (p-value = 0.003). CONCLUSIONS: OPC and
TC represent a substantial ﬁnancial burden on patients and car-
egivers. A vast majority of caregivers report adverse work
impact. These results support the need for programs aimed at
alleviating the economic burden stemming from care-related
activities that are increasingly being shifted towards informal
caregivers and patients.
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Health care costs are virtual and depend upon the criteria chosen.
Costs considered for economic evaluations vary according to the
objective of the study, comparators, analysis perspective, time
horizon and stage of the disease. OBJECTIVES: Our research
objective is to create a toolkit compiling relevant and exhaustive
information about costs needed to conduct an economic evalu-
ation for cancer. METHODS: Economic French data were exten-
sively collected within Internet sites, French ofﬁcial journals,
health insurance and hospital databases, IRDES, INSEE, per-
sonal contacts with health economics professionals. We check-
listed the costs to build a table showing the different type of costs,
how and when these costs can be used, where they can be found.
Consistent references, data sources are included. RESULTS:
Cancer costs can be split into induced and avoided costs. If costs
of chemotherapy (acquisition, administration) are usually well
known, others are not easily comprehensive and accessible such
as: costs of complications, adverse events, transportations, costs
of follow-up, of time lost, of ambulatory care, costs of adapting
home, sick pay for medical disorders . . . For example, to calcu-
late the cost of loss of productivity, we need French average
annual income. Available INSEE data provide average incomes
per year, per sector (private or public), per social and work
classes, per sex, per age. If these items are perfectly identiﬁed a
priori they can be directly collected in Case Report Form to
enhance prospective data management. In the same way, costs of
transportation could be easily available indeed they are calcu-
lated with a scale established by ministerial decree. CONCLU-
SIONS: Clearly identifying and making easily available economic
data could reduce process of economic assessment. Taking into
account standard costs would simplify economics studies and
increase their production. Comprehensive and exhaustive costs
tables are intended to be useful for decision-makers, in particular
for Health Technology Assessment.
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